Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

BACKGROUND: The high incidence and mortality of lung cancer have seriously affected human life and health. Nivolumab is a monoclonal antibody that can inhibit programmed death 1 (PD-1) and Ipilimumab is a monoclonal antibody against CTLA-4(cytotoxic T lymphocyte-associated antigen 4), both of which...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Huihui, Xu, Aiqun, Xia, Wanli, Xia, Xingyuan, Li, Pulin, Zhang, Binbin, Zhu, Ke, Zhou, Sijing, Wang, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364020/
https://www.ncbi.nlm.nih.gov/pubmed/34391428
http://dx.doi.org/10.1186/s12935-021-02100-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364020/
https://www.ncbi.nlm.nih.gov/pubmed/34391428
http://dx.doi.org/10.1186/s12935-021-02100-w

Ejemplares similares